# ARBLI

Product · id `cardio:fdaprod-nda218772` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [openFDA record NDA218772](<https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA218772>), retrieved 18 November 2026. No person wrote or checked this page.

Browse, organ or system: Blood vessels; Brain; Kidneys  
Browse, condition area: High blood pressure; Stroke; Kidney connections  

## In plain language

A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

## Technical summary

Drugs@FDA application NDA218772. Original approval 2025-03-13. No efficacy supplement approvals are on record. 1 product listed.

## The registry's words

- Application: NDA218772
- Brand name: ARBLI
- Applicant: SCIENTURE
- Active ingredient: LOSARTAN POTASSIUM
- Dosage form: SUSPENSION
- Route: ORAL

## Claims, with the population each applies to

## Context: FDA record read by the openFDA feed

Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)

### FDA records an approval of NDA218772 on 2025-03-13.

- Category: Regulatory
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Limitations: Assembled by a program from openFDA; the approved uses are in the FDA label, which this record does not read. openFDA says its data is unvalidated and not for medical decisions.
- Last checked: Not recorded
- Sources:
  1. Supports: Drugs@FDA application NDA218772 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA218772>
     Locator: submissions\[0\].submission\_status\_date. Retrieved 2026-11-18T16:02:16Z. Source state: Current. Version fingerprint: c30467e29c3ccea1b8da5cc013270386ed9a1da00feaa02008723bdf077f9c46.
     How it applies: The decision date as the record writes it.
  2. Supports: Drugs@FDA application NDA218772 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA218772>
     Locator: application\_number. Retrieved 2026-11-18T16:02:16Z. Source state: Current. Version fingerprint: c30467e29c3ccea1b8da5cc013270386ed9a1da00feaa02008723bdf077f9c46.
     How it applies: The registry number of the record.
  3. Supports: Drugs@FDA application NDA218772 (openFDA record) (Regulator) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA218772>
     Locator: submissions\[0\].submission\_status. Retrieved 2026-11-18T16:02:16Z. Source state: Current. Version fingerprint: c30467e29c3ccea1b8da5cc013270386ed9a1da00feaa02008723bdf077f9c46.
     How it applies: The decision status as the record writes it.

## Guidance, authorization and access

### Regulatory decision `cardio:fdadec-nda218772-approval`

- Product: ARBLI (`cardio:fdaprod-nda218772`)
- Authority: U.S. Food and Drug Administration (`core:fda`)
- Decision: Approval, 2025-03-13
- Product version: Original application
- Pathway: NDA
- Submission: NDA218772
- Indication: Not stated in the openFDA record
- Jurisdictions: United States
- Applies to: Recipient: Recipient not specified; Population: Not stated in the openFDA record; Care setting: Not stated in the openFDA record; Geography: United States (a decision by the US Food and Drug Administration); Life stage: Not stated in the openFDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Basis: claim `cardio:fdaclaim-nda218772-approval`

## Connected pages

- Registry active ingredient is this drug: Losartan (`cardio:losartan`)

## Provenance

Content hash: 75f4c8ea021d0b37a27de7c6cb8dd5be7d344b54caa93f451d9a9fd0e7eca20d
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
